| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| VOXZOGO | $183.92M | $189.79M | $208.5M | $213.75M | $221.39M | $218.39M | $273.39M | $219.88M |
| VIMIZIM | $178.02M | $178.16M | $191.09M | $188.35M | $215.42M | $182.76M | $205.53M | $210.2M |
| NAGLAZYME | $132.05M | $131.91M | $110M | $114.29M | $128.87M | $122.03M | $120.22M | $130.07M |
| PALYNZIQ | $88.29M | $90.63M | $100.41M | $93.27M | $105.94M | $108.78M | $125.33M | $89.56M |
| BRINEURA | $45.31M | $37.01M | $47.72M | $40.36M | $48.69M | $47.95M | $49.39M | $47.1M |
| ALDURAZYME | $38.56M | $71.03M | $39.04M | $48.98M | $56.44M | $53.71M | $49.39M | $36.74M |
| KUVAN | $28.55M | $28.12M | $28.33M | $25.14M | $27.03M | $24.03M | $23.34M | $23.88M |
| Royalty and other revenues | $9.9M | $11.87M | $11.68M | $10.5M | $12.43M | $15.32M | $15.24M | $6.13M |
| ROCTAVIAN | $7.43M | $7.24M | $10.55M | $10.51M | $9.2M | $3.18M | $12.75M | $2.64M |
| Total | $712.03M | $745.74M | $747.31M | $745.15M | $825.41M | $776.13M | $874.57M | $766.21M |